Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487328 | 0.91 | PKM (0.41) | PKMMAPK1HSD17B10CYP19A1CA12 | |
| SCHEMBL6635716 | 0.87 | CYP19A1 (0.46) | PKMMAPK1HSD17B10CYP19A1CA12 | |
| Butane SCHEMBL6828567 | 0.81 | CYP19A1 (0.42) | PKMMAPK1HSD17B10CYP19A1CA12 | |
| Bicarbonate SCHEMBL28723134 | 0.80 | CA1 (0.46) | PKMMAPK1HSD17B10CYP19A1CA12 | |
| SCHEMBL610682 | 0.80 | CA1 (0.50) | PKMMAPK1HSD17B10CYP19A1CA12 | |
| SCHEMBL17075163 | 0.80 | CA1 (0.50) | PKMMAPK1HSD17B10CYP19A1CA12 | |
| SCHEMBL305153 | 0.76 | MAPK1 (0.47) | PKMMAPK1HSD17B10CYP19A1CA12 | |
| SCHEMBL2267201 | 0.76 | CYP19A1 (0.50) | PKMMAPK1HSD17B10CYP19A1CA12 | |
| SCHEMBL4479713 | 0.76 | TSHR (0.35) | GAALMNA | |
| SCHEMBL4489180 | 0.75 | MMP1 (0.44) | MAPK1CA2TDP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553989-B2 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-30 | — | — | US | claimed |
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA LTD. (JP) | 2005-12-08 | — | — | US | claimed |
| EP-1561748-A1 | MALONIC ACID MONOESTERS AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-10 | — | — | EP | claimed |
| US-7553989-B2 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1561748-A1 | MALONIC ACID MONOESTERS AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | ME1, SI, ME3 | PKM 300/4885MAPK1 524/4885HSD17B10 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.